The totality of evidence suggests that ANGPTL3 inhibition seems to be a better target for the treatment of hypercholesterolemia than sHTG, while apo-CIII seems to be much more promising for the treatment of sHTG and has at best no or negative effects on LDL-C levels. This evidence concerns the gene ANGPTL3 and familial hypercholesterolemia.